Educational guide
Ipamorelin: Research Profile | Palmetto Peptides
Ipamorelin: Research Profile Research Notice: This article covers research on Ipamorelin research peptide and CJC-1295 without DAC research peptide — available from Palmetto Peptides for laboratory use only. Ipamorelin is a synthetic pentapeptide growth hormon
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Ipamorelin: Research Profile
Research Notice: This article covers research on Ipamorelin research peptide and CJC-1295 without DAC research peptide — available from Palmetto Peptides for laboratory use only.
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) — Aib-His-D-2-Nal-D-Phe-Lys-NH2 — developed by Novo Nordisk and first described in 1998. It is a selective agonist of the growth hormone secretagogue receptor (GHSR-1a), also known as the ghrelin receptor, and stimulates growth hormone (GH) release from the anterior pituitary with high selectivity and minimal effects on cortisol, prolactin, or ACTH secretion at research doses. This selectivity profile, combined with its potency and safety in preclinical models, has made ipamorelin one of the most studied growth hormone-releasing peptides (GHRPs) in research literature.
Last Updated: April 1, 2026 | Reading Time: Approximately ~7 minutes | Author: Palmetto Peptides Research Team
Quick Answer
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide growth hormone secretagogue that selectively activates the ghrelin receptor (GHSR-1a) on pituitary somatotroph cells. First described by Novo Nordisk in 1998, it is distinguished from earlier GHRPs by its relative selectivity for GH secretion over cortisol and ACTH stimulation in preclinical research. Researchers use Ipamorelin to study pituitary GH regulation and frequently combine it with CJC-1295 to investigate complementary GH secretagogue mechanisms.
Structure and Classification
Ipamorelin belongs to the GHRP family — synthetic pentapeptides that mimic ghrelin's action at GHSR-1a. The key structural feature distinguishing ipamorelin from earlier GHRPs (GHRP-2, GHRP-6, hexarelin) is the incorporation of D-2-naphthylalanine (D-2-Nal) at position 3, which confers exceptional GHSR-1a selectivity and eliminates the off-target receptor interactions that cause cortisol and prolactin release seen with earlier GHRPs.
The five amino acids of ipamorelin are: Aib (alpha-aminoisobutyric acid, N-terminal) - His - D-2-Nal - D-Phe - Lys-NH2 (C-terminal amide). The D-amino acids (D-2-Nal and D-Phe) confer resistance to proteolytic degradation, extending the plasma half-life to approximately 2 hours compared to minutes for native ghrelin. The C-terminal amide improves receptor binding and metabolic stability.
Mechanism of Action
GHSR-1a Activation
Ipamorelin binds GHSR-1a — a Gq/11-coupled G protein-coupled receptor expressed primarily on somatotroph cells in the anterior pituitary, but also in the hypothalamus, hippocampus, and peripheral tissues. Upon binding, GHSR-1a activates phospholipase C, generating IP3 and DAG, which mobilize intracellular calcium stores and activate protein kinase C. This calcium signal triggers GH vesicle exocytosis from somatotrophs, producing a robust GH pulse.
Selectivity for GH vs. Other Hormones
A landmark comparative study by Raun et al. (1998) — the original ipamorelin publication — directly compared ipamorelin's hormonal selectivity to GHRP-6 and GHRP-2 in rat models. Results demonstrated:
Ipamorelin produced GH release equivalent to or exceeding GHRP-6 and GHRP-2
Ipamorelin did not significantly stimulate ACTH or cortisol release at doses producing maximal GH secretion
Ipamorelin did not elevate prolactin at research doses, unlike hexarelin which causes significant prolactin release through D2 receptor interactions
The selectivity was attributed to ipamorelin's near-exclusive GHSR-1a binding versus the broader receptor profiles of earlier GHRPs
Synergy with GHRH Analogs
Ipamorelin and GHRH analogs such as Sermorelin, CJC-1295 Without DAC, and CJC-1295 with DAC act through complementary mechanisms. GHRPs stimulate GH release by activating GHSR-1a and reducing somatostatin tone, while GHRH analogs stimulate GH synthesis and release through GHRH receptor activation. Co-administration produces synergistic GH pulse amplitudes substantially greater than either compound alone — a well-replicated finding that has made ipamorelin/GHRH analog combinations a standard research protocol.
Key Research Findings
GH Pulse Dynamics
Ipamorelin produces pulsatile GH release consistent with physiological GH secretion patterns. Research examining pulse dynamics has shown that GH levels peak approximately 15–30 minutes post-administration and return to baseline within 2–4 hours. This pulsatile pattern preserves the physiological GH secretion rhythm that is important for normal IGF-1 signaling and GH receptor sensitivity — a potential advantage over compounds that produce sustained GH elevation.
Body Composition Research
Chronic ipamorelin administration studies in rodent models have reported increased lean body mass, reduced adiposity, and improved body composition metrics. Research in aged rats showed ipamorelin reversed age-related declines in GH pulse amplitude and produced body composition changes consistent with anabolic GH action. These findings have generated research interest in GHRPs as tools for studying somatopause (age-related GH decline) and potential interventional approaches.
Bone Density Research
An interesting finding in ipamorelin research — noted in the original Novo Nordisk studies — was its apparent effects on bone mineral density in rodent models. Chronic administration was associated with increased femoral bone density and improved bone quality markers, consistent with the known anabolic effects of GH/IGF-1 on bone metabolism. This has motivated research into GHRPs as tools for studying osteoporosis and age-related bone loss.
GI Motility Research
GHSR-1a is expressed in the enteric nervous system, and ghrelin/GHSR agonists are known to promote gastrointestinal motility. Research has documented ipamorelin's prokinetic effects in rodent and ex vivo gut models, with findings relevant to research on post-operative ileus and gastroparesis. This peripheral GHSR-1a activity represents an aspect of ipamorelin's research profile distinct from its pituitary GH-releasing action.
Comparison with Other GHRPs
GHRP-2: More potent than ipamorelin for GH release but significant cortisol and prolactin elevation. Research requiring GH stimulation without HPA axis activation favors ipamorelin.
GHRP-6: Classic reference compound; produces significant ghrelin-like appetite stimulation through peripheral GHSR-1a, unlike ipamorelin which shows less pronounced appetite effects.
Hexarelin: Most potent GHRP but develops rapid desensitization (tachyphylaxis) and has significant cardiovascular effects through CD36 receptor binding — distinct from ipamorelin's cleaner GHSR-1a profile.
MK-677 (Ibutamoren): Oral GHSR-1a agonist with similar selectivity to ipamorelin but much longer half-life (~24 hours), enabling oral administration — relevant for research where subcutaneous injections are impractical.
Frequently Asked Questions
Why is ipamorelin's selectivity considered important for research?
When studying GH-specific effects, off-target cortisol or prolactin elevation complicates interpretation of results. Ipamorelin's selectivity allows researchers to attribute observed effects to GH/IGF-1 axis activation with greater confidence, making it a cleaner pharmacological tool for somatotropic research.
How does ipamorelin compare to native ghrelin as a research tool?
Native ghrelin has a plasma half-life of ~20 minutes and requires acylation for receptor activation. Ipamorelin's resistance to proteolysis (~2-hour half-life), high receptor selectivity, and consistent GH release make it a more practical and reproducible research tool than native ghrelin for most pituitary-focused studies.
What reconstitution is recommended for ipamorelin research?
Ipamorelin is typically reconstituted in bacteriostatic water or isotonic saline. Reconstituted solutions are stable at 2–8°C for up to 28 days. The lyophilized powder is stable at room temperature for short-term storage but benefits from refrigeration for longer storage periods.
References
Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. PMID: 9849822
Johansen PB, et al. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. PMID: 10075046
Svensson J, et al. (2000). Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology & Metabolism. PMID: 10998745
Disclaimer: All compounds offered by Palmetto Peptides are strictly for laboratory research and in vitro studies. They are not intended for human consumption, veterinary use, or any therapeutic application. All information provided is for educational and scientific reference only. Palmetto Peptides makes no health claims. Consult a licensed medical professional before handling any research compound.
Related Research: How to Supplement for Ultimate Health: An Evidence-Based Stack | Top 10 Peptides of the Future: What Research Suggests | Why Peptides Matter in Research: A Scientific Perspective
Related Research
What Are Growth Hormone Peptides?
Sermorelin: Research Profile
Tesamorelin: Clinical Research Overview
Hexarelin: Research Profile
Related research: sermorelin research, hexarelin vs ipamorelin comparison, and CJC-1295 and ipamorelin research stack.
More Research Articles
Where to Buy High-Purity Sermorelin Research Peptide: Quality and Supplier Guide
Jul 8, 2026